FDA Clearance, Management Changes, and Clinical Study Updates - Research Report on Illumina, Array, Oncolytics, Intrexon, and STERIS Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 26, 2013 NEW YORK, November 26, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Illumina, Inc. (NASDAQ: ILMN), Array BioPharma Inc. (NASDAQ: ARRY), Oncolytics Biotech, Inc. (NASDAQ: INCY), Intrexon Corporation (NYSE: XON), and STERIS Corporation (NYSE: STE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Illumina, Inc. Research Report On November 19, 2013, Illumina, Inc. (Illumina) announced that it has received premarket clearance from the US FDA for the MiSeqDx system, the first high-throughput DNA sequencing analyzer to receive FDA clearance. In addition, the Company also reported that it has received FDA premarket clearance for MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit. "Illumina is proud to be the first company to obtain FDA clearance for a high-throughput DNA sequencing analyzer and next-generation sequencing-based assays," said Greg Heath, Senior Vice President and General Manager of Illumina's Diagnostics business. "With the FDA clearance of the MiSeqDx, Illumina is providing clinicians and clinical laboratories with the tools needed to obtain comprehensive and reliable results from a DNA sequencing analyzer and enabling them to create and deploy NGS-based molecular diagnostic tests for cystic fibrosis and a wide-range of other applications." The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/3cf2_ILMN -- Array BioPharma Inc. Research Report On November 21, 2013, Array BioPharma Inc. (Array) announced that Kevin Koch, Ph.D., its President and Chief Scientific Officer, will be leaving the Company to pursue other opportunities. "The board and executive team thank Dr. Koch for his leadership and contributions to the success of Array over the past 15 years. During this time, Array advanced 19 novel compounds into clinical trials, of which 14 remain in active development," said Ron Squarer, CEO of Array. "With several of these programs in late stage trials, and a strong management team in place, Array is well-positioned for continued success." The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e048_ARRY -- Oncolytics Biotech, Inc. Research Report On November 21, 2013, Oncolytics Biotech, Inc. (Oncolytics) announced positive top-line data for the endpoints in its double blinded, randomized clinical study that examined REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers. "The overall goal of this clinical trial was to determine the specific parameters for the use of REOLYSIN in a registration study in head and neck cancers," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are excited to move forward with our head and neck program, and intend to discuss the design and execution of a follow-on registration study with regulators in the near future." The Full Research Report on Oncolytics Biotech, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/0c64_ONCY -- Intrexon Corporation Research Report On November 18, 2013, Intrexon Corporation (Intrexon) announced the appointments of Peter Seufer-Wasserthal, Ph.D., and Dana Di Ferdinando to the positions of Vice President of Business Development for Europe and Asia, and Chief Information Officer, respectively, effective immediately. "We are excited to have Ms. Di Ferdinando and Dr. Seufer-Wasserthal join Intrexon at this stage of our growth. Dana will lead development of the next generation of Intrexon's proprietary technologies, particularly UltraVector®, an industry-leading software platform that enables our collaborators to design, test, and produce complex biological solutions with the goal of generating superior commercial products. Peter will expand Intrexon's presence even further into Europe and Asia, growing our international relationships to establish additional collaborations abroad. I am confident that their respective professional experiences and insights will be a tremendous asset to Intrexon," said Krish Krishnan, Chief Operating Officer of Intrexon. The Full Research Report on Intrexon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cb5c_XON -- STERIS Corporation Research Report On October 30, 2013, STERIS Corporation (STERIS) reported Q2 FY 2014 financial results (period ended September 30, 2013). In Q2 FY 2014, the Company achieved net revenues of $383.8 million, up 7.7% YoY. Q2 FY 2014 net income was $29.7 million, or $0.50 per diluted share, compared with net income of $40.1 million, or $0.68 per diluted share, in Q2 FY 2013. "We are pleased that our performance returned to expectations this quarter, reflecting the continued growth in our end-markets and success with new products," said Walt Rosebrough, President and CEO of STERIS. "With solid organic growth across all segments and strong backlog, we have confidence in our ability to produce a strong second half of the year. Due largely to the timing of investments for our in-sourcing projects, we now anticipate that earnings will be in the lower half of our previously provided range of $2.47 to $2.60 for the full fiscal year." The Full Research Report on STERIS Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8e31_STE ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
FDA Clearance, Management Changes, and Clinical Study Updates - Research Report on Illumina, Array, Oncolytics, Intrexon, and
Press spacebar to pause and continue. Press esc to stop.